Key result
Euglycemic hyperinsulinemia links to greater systolic BP drops but less microvascular expansion in cardiometabolic risk groups.
Why the study?
Insulin's vasodilatory actions and capillary recruitment are diminished by insulin resistance, but interactions between insulin's acute actions on blood pressure and capillary recruitment in cardio-metabolic disease risk groups remained unclear.
Does acute insulin administration alter blood pressure and microvascular perfusion differently in persons with cardio-metabolic disease compared to healthy controls?
Observational
Does acute insulin administration alter blood pressure and microvascular perfusion differently in persons with cardio-metabolic disease compared to healthy controls?
In individuals with cardio-metabolic disease, acute insulin administration lowers blood pressure and decreases distal microvascular perfusion, highlighting significant microvascular dysfunction.
Suggests microvascular dysfunction in CMD risk groups; leaves open causal implications for practice or outcomes.
In healthy humans, insulin at physiological concentrations exerts acute vasodilatory actions on both resistance and terminal arterioles, leading, respectively, to increased total blood flow and the microvascular network volume being perfused. The process of increasing capillary network volume is frequently referred to as “capillary recruitment”. Together these two vascular actions of insulin enhance the delivery of oxygen, nutrients, and insulin itself to tissues. Both processes are diminished by insulin resistance. Here we examined interactions between insulin’s acute (within 2 h) actions on blood pressure (both central and peripheral) and on capillary recruitment in healthy controls and in four distinct groups of people with heightened cardio-metabolic disease (CMD) risk: individuals with obesity, metabolic syndrome, and type 1 or type 2 diabetes. Insulin increased microvascular blood volume (MBV) more effectively in controls than in each of the four CMD risk groups (p < 0.001). Conversely, insulin lowered both central and peripheral systolic pressure (p < 0.05 or less) in each of the CMD risk groups but not in the controls. The insulin-induced blood pressure decrements were greater in the metabolic syndrome, type 2 diabetes, and obesity groups (p < 0.05 or less) than in the controls. The greater blood pressure declines likely reflect decreased sympathetic baroreceptor reflex tone. These effects on blood pressure combined with the diminished dilation of terminal arterioles due to microvascular insulin resistance in the CMD risk subjects led to decreased distal microvascular perfusion as evidenced by changes in MBV. These findings highlight the complex interplay between insulin’s actions on resistance and terminal arterioles in individuals with a high CMD risk, underscoring the importance of addressing microvascular dysfunction in these conditions.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2025) conducted an observational in Cardio-metabolic disease risk (obesity, metabolic syndrome, type 1 or type 2 diabetes). Insulin (Euglycemic hyperinsulinemia) vs. Healthy controls was evaluated on Microvascular blood volume (MBV) and systolic blood pressure (p=<0.001). Euglycemic hyperinsulinemia lowered systolic blood pressure more but increased microvascular blood volume less in cardio-metabolic disease risk groups compared to healthy controls (p<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: